Importance of cardiac biomarkers in risk stratification in acute pulmonary embolism

Cardiology Journal

Volumn 15, Issue 1, 2008, Pages 17-20

  Mikulewicz, Małgorzata ^a   Lewczuk, Jerzy ^a  

^a 51 124   (Poland)

Author keywords

Acute pulmonary embolism; Cardiac biomarkers; Risk stratification

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; FIBRINOLYTIC AGENT; MYOGLOBIN; TROPONIN I; TROPONIN T;

ACUTE DISEASE; ALGORITHM; CARDIOPULMONARY HEMODYNAMICS; CHRONIC DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; ELECTROCARDIOGRAPHY; HEART MUSCLE NECROSIS; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE OVERLOAD; HUMAN; LUNG EMBOLISM; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PULMONARY HYPERTENSION; REVIEW; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM;

ACUTE DISEASE; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; TROPONIN; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 41149090120     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Kostrubiec M, Bochowicz A, Pruszczyk P. Biochemiczne wskaźniki uszkodzenia i przeciażenia serca w ocenie ryzyka chorych z ostrá zatorowościa płucna. Kardiol Pol, 2004; 61: 277.
2. Andrade de la Cal FJ, Aguado Borruey JM, Narvaez Bermcjo JM et al. Pulmonary embolism and occult right ventricular infarction. Chest, 1994; 105: 1617.
3. Mittal SR, Arora H. Pulmonary embolism with isolated right ventricular infarction. Indian Heart J, 2001; 53: 218-220.
4. Pruszczyk P, Bochowicz A, Kostrubiec M et al. Myoglobin stratifies short-term risk in acute major pulmonary embolism. Clin Chim Acta, 2003; 338: 53-56.
5. Kaczynska A, Pelsers MM, Bochowicz; A et al. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta, 2006; 371: 117-123.
6. Puls M, Dellas C, Lankeit M et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J, 2006; 24: 119.
7. Katus HA, Remppis A, Neumann FJ et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation, 1991; 83: 909-912.
8. Muller-Bardorff M, Weidtmann B, Giannitsis E et al. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem, 2002; 48: 673-675.
9. Giannitsis E, Muller-Bardorff M, Kurowski V et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation, 2000; 102: 211-217.
10. Konstantinides S, Geibel A, Olschewski M et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation, 2002; 106: 1263-1268.
11. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet, 1999; 353: 1386-1389.
12. Pruszczyk P, Bochowicz A, Torbicki A et al. Cardiac troponin T monitoring identifies high risk group of normotensive patients with acute pulmonary embolism. Chest, 2003; 123: 1947-1952.
13. Janata K, Holzer M, Laggner AN, Mullner M. Cardiac troponin T in the severity assessment of patients with pulmonary embolism: cohort study. BMJ, 2003; 326: 312-313.
14. Konstantinides S, Geibel A, Hensel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med, 2002; 347: 1143-1150.
15. Mueller C, Scholer A, Laule-Kilian K. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med, 2004; 350: 647-654.
16. Berger R, Huelsman M, Strecker K et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation, 2002; 105: 2392-2397.
17. Kurose M, Yosimura M, Yasue H. Raised plasma BNP in patients with pulmonary thromboembolism. Heart, 1997; 78: 320-321.
18. Tulevski II, Hirsch A, Sanson BJ et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost, 2001; 86: 1193-1196.
19. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation, 2003; 107: 2545-2547.
20. Pieralli F, Olivotto I, Vanni S et al. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol, 2006; 97: 1386-1390.
21. Pruszczyk P, Kostrubiec M, Bochowicz A et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J, 2003; 22: 649-653.
22. Kucher N, Printzen G, Doernhoefer T et al. Low pro-brain natriuretic peptide levels predict begin clinical outcome in acute pulmonary embolism. Circulation, 2003; 107: 2545.
23. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation, 2003; 108: 2191-2194.
24. Kostrubiec M, Pruszczyk P, Bochowicz A et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J, 2005; 26: 2166-2172.
25. Wolde M, Tulevski II, Mulder JW et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation, 2003; 107: 2082-2084.
26. Tulevski II, Wolde MT, van Veldhuisen DJ et al. Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. Int J Cardiol, 2007; 116: 161-166.